Illumina

Illumina leads the DNA sequencing market with next-generation sequencing platforms, controlling ~80% global share and reducing genome sequencing costs to ~$200.

历史时间线

• 1998: Founded in San Diego by Larry Bock, John Stuelpnagel, and others
• 2006: Acquires Solexa, gains bridge amplification technology
• 2007: Goes public, rapid growth in genomics research market
• 2014: NovaSeq launches — highest-throughput sequencer at the time
• 2018: NovaSeq 6000 reduces genome sequencing cost to ~$200
• 2021: Acquires Grail (cancer blood test company) for $7.1B
• 2022: EU orders Illumina to divest Grail (antitrust)
• 2024: Completes Grail divestiture, refocuses on core sequencing

商业模式

DNA sequencing instruments, consumables (flow cells, reagents), and bioinformatics. 'Razor and blades' model — sells instruments at competitive prices, generates recurring revenue from high-margin consumables. NovaSeq and NextSeq platforms dominate research and clinical markets.

护城河分析

~80% market share in DNA sequencing — near monopoly. Installed base of instruments creates locked-in consumables revenue. Technology lead in accuracy and throughput. Network effects from bioinformatics ecosystem.

关键数据

• Founded: 1998, San Diego, California
• Revenue 2023: ~$4.5B
• Market Share: ~80% of NGS market
• Employees: ~10,000
• Genome Sequencing Cost: ~$200 (vs. $100M in 2001)

有趣事实

• Illumina's technology has reduced the cost of sequencing a human genome from ~$100 million in 2001 to about $200 today — faster than Moore's Law.
• The Grail acquisition and forced divestiture became one of the most consequential antitrust cases in biotech history — the EU literally forced Illumina to undo a $7.1B deal.